MNOV MediciNova
- 1.960
- -0.030-1.51%
- 1.960
- 0.0000.00%
MediciNova News
MediciNova Presents Study Update And Interim Analysis Of Phase 2/3 Clinical Trial Of MN-166 In ALS At The 35th International Symposium On ALS/MND
Express News | MediciNova Inc - Expects to Complete Patient Assignments by June 2025 With Trial Results Expected in 2026
Express News | MediciNova Inc - Positive Correlations Observed Between 6-Month and 12-Month Data
Express News | Medicinova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of Mn-166 (Ibudilast) in ALS (Combat-ALS Clinical Trial) at the 35TH International Symposium on ALS/Mnd
Volume change rate ranking (9 AM period) - Nishiwa Industries, WealthNavi, etc. are ranked.
※In the volume change rate ranking, you can understand the interest of market participants such as trends in inquiries by comparing the average volume of the past 5 days with the volume on the day of distribution.■Volume Change Rate Top [As of 9:34 on December 3] (Comparison with average volume of the past 5 days) Stock Code Stock Name Volume 5-Day Average Volume Volume Change Rate Stock Price Change Rate ＜7342＞ WealthNavi 3479800 10718 5.08 305.83% 0.17% ＜2634＞
This Autodesk Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
D. Boral Capital Initiates MediciNova(MNOV.US) With Buy Rating, Announces Target Price $9
D. Boral Capital Initiates Coverage On MediciNova With Buy Rating, Announces Price Target of $9
MediciNova Analyst Ratings
MediciNova Highlights Strategic Focus On Non-Dilutive Funding With NIH-Funded ALS Trial And Canadian Long COVID Study, Reports Strong $42.3M Cash Position, And Reaffirms Commitment To Sustainable Growth And Shareholder Transparency
MediciNova Provides Update in Letter to Stockholders
Express News | Medicinova CEO Yuichi Iwaki Provides Corporate Update in Letter to Stockholders
MediciNova Granted Notice of Allowance for MN-001 Patent by USPTO
Express News | MediciNova Receives Notice Of Allowance From US PTO For A Pending Patent Application For MN-001 (Tipelukast) To Cover 'Method To Decrease Triglyceride Synthesis In A Liver Of A Subject'
Express News | MediciNova Inc - Patent Is Expected to Expire No Earlier Than May 26, 2042
Express News | Medicinova Receives Notice of Allowance From United States Patent and Trademark Office for New Patent Covering Mn-001 for Triglyceride Synthesis in the Liver
MediciNova: Supplementary explanation of financial results for the 3rd quarter of the fiscal year ending 2024/12
MediciNova | 10-Q: Q3 2024 Earnings Report
MediciNova: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [US GAAP] (consolidated)
MediciNova: Q3 Earnings Snapshot
No Data